Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2135MR)

This product GTTS-WQ2135MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2135MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15975MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ13790MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ9807MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ10300MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ6073MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ13078MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8454MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ12070MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOR-00208
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW